<SEC-DOCUMENT>0001004878-15-000293.txt : 20151015
<SEC-HEADER>0001004878-15-000293.hdr.sgml : 20151015
<ACCEPTANCE-DATETIME>20151015162508
ACCESSION NUMBER:		0001004878-15-000293
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20151011
ITEM INFORMATION:		Entry into a Material Definitive Agreement
FILED AS OF DATE:		20151015
DATE AS OF CHANGE:		20151015

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11889
		FILM NUMBER:		151160350

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8kitem101declara10-15.txt
<DESCRIPTION>FORM 8-K ITEM 1.01
<TEXT>
                                 UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

       Date of Report (date of earliest event reported): October 11, 2015

                               CEL-SCI CORPORATION
                        ---------------------------------
             (Exact name of Registrant as specified in its charter)



          Colorado                      01-11889               84-0916344
   -----------------------          ----------------        ----------------
(State or other jurisdiction      (Commission File No.)   (IRS Employer
of incorporation)                                          Identification No.)


                         8229 Boone Boulevard, Suite 802
                             Vienna, Virginia 22182
                   -----------------------------------------
          (Address of principal executive offices, including Zip Code)


       Registrant's telephone number, including area code: (703) 506-9460

                                       N/A
                   ------------------------------------------
          (Former name or former address if changed since last report)

Check appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy  the filing  obligation  of the  registrant  under any of the  following
provisions (see General Instruction A.2. below)

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
    230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
    240.14a-12)

[ ] Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
    Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement  communications  pursuant to Rule 13e-14(c) under the
    Exchange Act (17 CFR 240.13e-4(c))

<PAGE>

Item 1.01   Entry Into a Material Definitive Agreement

     On December 28, 2008, the Company issued a promissory note to Maximilian de
Clara,  the  Company's  President and a director.  In August 2014,  the Note was
transferred  to the de Clara Trust.  The  maturity  date on the note was July 6,
2017.

     On October 11, 2015 the parties  agreed to extend the maturity  date of the
Note for one year to July 6, 2018. The extension was made at the request of Lake
Whillans  Vehicle I, LLC, which, as disclosed in the Company's  October 14, 2015
press  release,  agreed to provide the Company with up to  $5,000,000 in funding
for litigation expenses to support the Company's $50,000,000  arbitration claims
against the Company's former clinical research organization.





                                       2
<PAGE>



                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Date:  October 15, 2015                   CEL-SCI CORPORATION


                                          By: /s/ Patricia B. Prichep
                                              --------------------------
                                              Patricia B. Prichep
                                              Senior Vice President of
                                              Operations
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
